Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial

BACKGROUND: Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control. Survival outcomes for patients with oligometastatic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Palma, David A, Haasbeek, Cornelis J A, Rodrigues, George B, Dahele, Max, Lock, Michael, Yaremko, Brian, Olson, Robert, Liu, Mitchell, Panarotto, Jason, Griffioen, GwendolynHMJ, Gaede, Stewart, Slotman, Ben, Senan, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433376/
https://www.ncbi.nlm.nih.gov/pubmed/22823994
http://dx.doi.org/10.1186/1471-2407-12-305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433376/
https://www.ncbi.nlm.nih.gov/pubmed/22823994
http://dx.doi.org/10.1186/1471-2407-12-305

Ejemplares similares